Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment FOXM1-specific siRNA
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature FoxM1
Official Symbol FOXM1
Mode of action PROT_D_DOWN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description We observed that both FOXM1 mRNA and protein levels were decreased when FOXM1-specific siRNA was transfected into the melanoma cells. And we found that the down-regulation of FOXM1 expression significantly inhibited melanoma cell proliferation.
PMID 26640950
Title Investigation of FOXM1 as a Potential New Target for Melanoma.